nach oben

Erschienen in:

16.08.2021 | Original Article

Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy

verfasst von: Makito Miyake, Nobutaka Nishimura, Yuki Oda, Takuya Owari, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Satoshi Anai, Kazumasa Torimoto, Katsuya Aoki, Tatsuo Yoneda, Tomomi Fujii, Nobumichi Tanaka, Kiyohide Fujimoto

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated sleep parameters and patient-reported outcomes before, during, and after induction Bacillus Calmette-Guerin therapy using questionnaires and actigraphy in patients with non-muscle invasive bladder cancer.

Methods

We investigated 10 patients who received Bacillus Calmette-Guerin therapy once weekly for 8 weeks. The International Prostate Symptom Score, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, Functional Assessment of Cancer Therapy-Bladder, and multi-item Short Form-8 tools were used to assess patient-reported outcomes. Participants completed all questionnaires before (baseline), at the 4th and 8th doses, and 1 month after the last Bacillus Calmette-Guerin dose. The MotionWatch8 was fastened to patients’ waist throughout the study. Composite sleep quality was determined based on sleep duration, efficiency, and fragmentation.

Results

We observed a transient increase in frequency/nocturia subscores and the insomnia subscore. The number of patients with poor sleep quality increased from 0 (0%) at baseline to 7 (70%) at the 4th dose and to 6 (60%) patients at the 8th dose. Among 10 patients, 6 (60%) were assigned to the sleep deterioration group and 4 (40%) to the non-deterioration group. Sleep quality was restored to baseline levels in 5 of 6 patients (83%) within 1 month after the last dose in the sleep deterioration group, and the nocturia subscore of the International Prostate Symptom Score was significantly increased only in this group (P=0.03).

Conclusions

This is the first study that confirms intravesical Bacillus Calmette-Guerin-induced sleep quality deterioration based on a questionnaire survey and actigraphy.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef

Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J et al (2019) European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol 76:639–657CrossRef

El Turabi A, Abel GA, Roland M, Lyratzopoulos G (2013) Variation in reported experience of involvement in cancer treatment decision making: evidence from the national cancer patient experience survey. Br J Cancer 109:780–787CrossRef

Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S et al (2021) Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur Urol 79:621–632CrossRef

Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R et al (2021) Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer 21:266CrossRef

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198:552–559CrossRef

Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M et al (2020) Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol 27:702–709CrossRef

Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD et al (2014) Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 66:1148–1156CrossRef

Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I et al (2013) The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol 190:857–862CrossRef

10.

Siracusano S, Silvestri T, Bassi S, Porcaro AB, Cerruto MA, Talamini R et al (2018) Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can J Urol 25:9480–9485PubMed

11.

Pesonen JS, Cartwright R, Vernooij RWM, Aoki Y, Agarwal A, Mangera A et al (2020) The impact of nocturia on mortality: a systematic review and meta-analysis. J Urol 203:486–495CrossRef

12.

Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S et al (1998) A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34:810–815CrossRef

13.

Degboe A, Ivanescu C, Rohay JM, Turner RR, Cella D (2019) Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients. Support Care Cancer 27:4189–4198CrossRef

14.

Tokuda Y, Okubo T, Ohde S, Jacobs J, Takahashi O, Omata F et al (2009) Assessing items on the SF-8 Japanese version for health-related quality of life: a psychometric analysis based on the nominal categories model of item response theory. Value Health 12:568–573CrossRef

15.

Miyake M, Tanaka N, Asakawa I, Hori S, Morizawa Y, Tatsumi Y et al (2017) Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. BMC Urol 17:62CrossRef

16.

Kurinami N, Sugiyama S, Nishimura H, Morita A, Yoshida A, Hieshima K et al (2018) Clinical factors associated with initial decrease in body-fat percentage induced by add-on sodium-glucose co-transporter 2 inhibitors in patient with type 2 diabetes mellitus. Clin Drug Investig 38:19–27CrossRef

17.

Keage HA, Banks S, Yang KL, Morgan K, Brayne C, Matthews FE (2012) What sleep characteristics predict cognitive decline in the elderly? Sleep Med 13:886–892CrossRef

18.

Landry GJ, Best JR, Liu-Ambrose T (2015) Measuring sleep quality in older adults: a comparison using subjective and objective methods. Front Aging Neurosci 7:166PubMedPubMedCentral

19.

Rutherford C, Patel MI, Tait MA, Smith DP, Costa DSJ, Sengupta S et al (2021) Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. Qual Life Res 30:345–366CrossRef

20.

Thulin H, Kreicbergs U, Wijkström H, Steineck G, Henningsohn L (2010) Sleep disturbances decrease self-assessed quality of life in individuals who have undergone cystectomy. J Urol 184:198–202CrossRef

21.

Hashim H, Blanker MH, Drake MJ, Djurhuus JC, Meijlink J, Morris V et al (2019) International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. Neurourol Urodyn 38:499–508CrossRef

22.

Bonnet MH, Arand DL (2003) Clinical effects of sleep fragmentation versus sleep deprivation. Sleep Med Rev 7:297–3210CrossRef

23.

Torimoto K, Hirayama A, Samma S, Yoshida K, Fujimoto K, Hirao Y (2009) The relationship between nocturnal polyuria and the distribution of body fluid: assessment by bioelectric impedance analysis. J Urol 181:219–224CrossRef

24.

Olesen T, Paul J, Gramme P, Drake MJ, Vandewalle J, Everaert K (2020) Assessment of the most impactful combination of factors associated with nocturia and to define nocturnal polyuria by multivariate modelling. J Clin Med 9:2262CrossRef

25.

Tsuneki H, Sasaoka T, Sakurai T (2016) Sleep control, GPCRs, and glucose metabolism. Trends Endocrinol Metab 27:633–642CrossRef

26.

Cheng TC, Lee YH, Chang YP, Lee DC (2020) Improved urinary melatonin level as the perspective indicator that leads to better sleeping quality in bladder cancer patients. Ther Adv Urol 12:1756287220940870CrossRef

27.

Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E et al (2008) Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 100:898–905CrossRef

28.

Liu S, Madu CO, Lu Y (2018) The role of melatonin in cancer development. Oncomedicine 3:37–47CrossRef

29.

Chen YT, Yang CC, Shao PL, Huang CR, Yip HK (2019) Melatonin-mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKT-MMP-9 signaling pathway. J Pineal Res 66:e12536CrossRef

Titel: Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy
verfasst von: Makito Miyake
Nobutaka Nishimura
Yuki Oda
Takuya Owari
Shunta Hori
Yosuke Morizawa
Daisuke Gotoh
Yasushi Nakai
Satoshi Anai
Kazumasa Torimoto
Katsuya Aoki
Tatsuo Yoneda
Tomomi Fujii
Nobumichi Tanaka
Kiyohide Fujimoto
Publikationsdatum: 16.08.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06468-3

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy